
A drug development services company providing a range of early stage and late stage product development services on a worldwide basis primarily to the pharmaceutical, biotechnology and medical device industries.
The best Bull and Bear pitches based on recency and number of recommendations.
Let’s face it, investing in drug developers isn’t easy. First, there’s the science risk – the chance that the company’s best drug prospect will fail somewhere during the arduous clinical trial and regulatory approval process. If that weren’t enough,… More
Read the most recent pitches from players about CVD.
Recs
Involved in R&D for pharma.
Recs
Evaluating a screen. Feel free to ignore.
Recs
just looking at the chart
Find the members with the highest scoring picks in CVD.
brendan310 (20.13) Score: +186.85
The Score Leader is the player with the highest score across all their picks in CVD.
Top Pick |
Member Name |
Member Rating |
Start Date |
Call |
Time Frame |
Start Price |
Stock Gain |
Index Gain |
Score | Commentary |
---|---|---|---|---|---|---|---|---|---|---|
brendan310 | 20.13 | 8/10/2009 |
![]() |
5Y | $54.72 | +94.48% | +281.33% | +186.85 | 0 Comment | |
lwc123 | 27.84 | 1/8/2009 |
![]() |
3Y | $41.95 | +153.68% | +331.55% | +177.86 | 0 Comment | |
epumple | < 20 | 6/24/2008 |
![]() |
NS | $82.89 | +28.39% | +198.49% | +170.10 | 6 Comments | |
woNroFeybdooG | 27.00 | 11/2/2009 |
![]() |
5Y | $51.90 | +105.05% | +267.17% | +162.12 | 0 Comment | |
j1wagner | < 20 | 4/28/2008 |
![]() |
3W | $85.49 | +24.48% | +183.58% | +159.10 | 0 Comment | |
![]() |
ben513 | 38.83 | 11/19/2009 |
![]() |
3M | $52.65 | +102.13% | +247.92% | +145.79 | 0 Comment |
pnouri | 75.73 | 10/1/2010 |
![]() |
5Y | $47.24 | +125.28% | +232.49% | +107.21 | 0 Comment | |
ajaskey | 50.77 | 8/25/2010 |
![]() |
NS | $38.50 | +176.42% | +264.30% | +87.88 | 0 Comment | |
joefcoelho100 | 60.61 | 9/2/2020 |
![]() |
5Y | $106.42 | 0% | +8.43% | -8.43 | 0 Comment | |
MrSLHolliday | 52.51 | 9/2/2020 |
![]() |
3W | $106.42 | 0% | +8.43% | -8.43 | 0 Comment |
See what the Wall Street professionals think, according to their public statements and filings.